FRANK E. MOTT

TitleAssociate Professor
InstitutionMD Anderson
DepartmentThoracic Head & Neck Medical Oncology
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Aggarwal P, Nader ME, Gidley PW, Pratihar R, Jivani S, Garden AS, Mott FE, Goepfert RP, Ogboe CW, Charles C, Fuller CD, Lai SY, Gunn GB, Sturgis EM, Hanna EY, Hutcheson KA, Shete S. Association of hearing loss and tinnitus symptoms with health-related quality of life among long-term oropharyngeal cancer survivors. Cancer Med. 2022 Jun 13. PMID: 35695117.
      Citations:    Fields:    
    2. Aggarwal P, Hutcheson KA, Yu R, Wang J, Fuller CD, Garden AS, Goepfert RP, Rigert J, Mott FE, Lu C, Lai SY, Gunn GB, Chambers MS, Li G, Wu CC, Hanna EY, Sturgis EM, Shete S. Genetic susceptibility to patient-reported xerostomia among long-term oropharyngeal cancer survivors. Sci Rep. 2022 04 22; 12(1):6662. PMID: 35459784.
      Citations: 1     Fields:    Translation:Humans
    3. Ferrarotto R, Amit M, Nagarajan P, Rubin ML, Yuan Y, Bell D, El-Naggar AK, Johnson JM, Morrison WH, Rosenthal DI, Glisson BS, Johnson FM, Lu C, Mott FE, Esmaeli B, Diaz EM, Gidley PW, Goepfert RP, Lewis CM, Weber RS, Wargo JA, Basu S, Duan F, Yadav SS, Sharma P, Allison JP, Myers JN, Gross ND. Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Apr 14; 28(8):1735. PMID: 35419587.
      Citations:    Fields:    
    4. Altan M, Singhi EK, Worst M, Carter BW, Leung CH, Lee JJ, Presley CJ, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Zhang J, Gibbons DL, Vaporciyan AA, Heymach JV, Mott FE. Clinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer. Clin Lung Cancer. 2022 05; 23(3):236-243. PMID: 35216923.
      Citations:    Fields:    Translation:Humans
    5. Aggarwal P, Hutcheson KA, Goepfert RP, Garden AS, Garg N, Mott FE, Fuller CD, Lai SY, Gunn GB, Chambers MS, Hanna EY, Sturgis EM, Shete S. Risk factors associated with patient-reported fatigue among long-term oropharyngeal carcinoma survivors. Head Neck. 2022 04; 44(4):952-963. PMID: 35084077.
      Citations:    Fields:    Translation:Humans
    6. Cognetti DM, Johnson JM, Curry JM, Kochuparambil ST, McDonald D, Mott F, Fidler MJ, Stenson K, Vasan NR, Razaq MA, Campana J, Ha P, Mann G, Ishida K, Garcia-Guzman M, Biel M, Gillenwater AM. Phase 1/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma. Head Neck. 2021 12; 43(12):3875-3887. PMID: 34626024.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    7. Lewis WE, Hong L, Mott FE, Simon G, Wu CC, Rinsurongkawong W, Lee JJ, Lam VK, Heymach JV, Zhang J, Le X. Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations. JTO Clin Res Rep. 2021 Nov; 2(11):100237. PMID: 34820641.
      Citations: 2     
    8. Elamin YY, Robichaux JP, Carter BW, Altan M, Gibbons DL, Fossella FV, Lam VK, Patel AB, Negrao MV, Le X, Mott FE, Zhang J, Feng L, Blumenschein G, Tsao AS, Heymach JV. Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial. J Clin Oncol. 2022 03 01; 40(7):702-709. PMID: 34550757.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    9. Aggarwal P, Hutcheson KA, Garden AS, Mott FE, Lu C, Goepfert RP, Fuller CD, Lai SY, Gunn GB, Chambers MS, Sturgis EM, Hanna EY, Shete S. Determinants of patient-reported xerostomia among long-term oropharyngeal cancer survivors. Cancer. 2021 12 01; 127(23):4470-4480. PMID: 34358341.
      Citations: 2     Fields:    Translation:Humans
    10. Aggarwal P, Hutcheson KA, Garden AS, Mott FE, Goepfert RP, Duvall A, Fuller CD, Lai SY, Gunn GB, Sturgis EM, Hanna EY, Shete S. Association of Risk Factors With Patient-Reported Voice and Speech Symptoms Among Long-term Survivors of Oropharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. 2021 07 01; 147(7):615-623. PMID: 33956062.
      Citations: 3     Fields:    Translation:Humans
    11. Ferrarotto R, Amit M, Nagarajan P, Rubin ML, Yuan Y, Bell D, El-Naggar AK, Johnson JM, Morrison WH, Rosenthal DI, Glisson BS, Johnson FM, Lu C, Mott FE, Esmaeli B, Diaz EM, Gidley PW, Goepfert RP, Lewis CM, Weber RS, Wargo JA, Basu S, Duan F, Yadav SS, Sharma P, Allison JP, Myers JN, Gross ND. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2021 08 15; 27(16):4557-4565. PMID: 34187851.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    12. Mott FE, Bruera E, Johnson F. End-of-life and goals of care discussions with cancer patients in the coronavirus pandemic. Palliat Support Care. 2021 06; 19(3):384-385. PMID: 32814600.
      Citations: 1     Fields:    Translation:HumansCellsPHPublic Health
    13. Guo TW, Saiyed F, Yao CMKL, Kiong KL, Martinez J, Sacks R, Lee JJ, Moreno AC, Frank SJ, Rosenthal DI, Glisson BS, Ferrarotto R, Mott FE, Johnson FM, Myers JN. Outcomes of patients with oropharyngeal squamous cell carcinoma treated with induction chemotherapy followed by concurrent chemoradiation compared with those treated with concurrent chemoradiation. Cancer. 2021 08 15; 127(16):2916-2925. PMID: 33873251.
      Citations:    Fields:    Translation:Humans
    14. Cascone T, William WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514. PMID: 33603241.
      Citations: 73     Fields:    Translation:HumansCTClinical Trials
    15. Tam S, Gajera M, Luo X, Glisson BS, Ferrarotto R, Johnson FM, Mott FE, Gillison ML, Lu C, Le X, Blumenschein GR, Wong MK, Rosenthal DI, Nagarajan P, El-Naggar AK, Midgen MR, Weber RS, Myers JN, Gross ND. Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck. Head Neck. 2021 05; 43(5):1592-1603. PMID: 33522021.
      Citations: 1     Fields:    Translation:Humans
    16. Christopherson KM, Moreno AC, Elgohari B, Gross N, Ferrarotto R, Mohamed ASR, Brandon Gunn G, Goepfert RP, Mott FE, Shah SJ, David Fuller C, Reddy JP, Frank SJ, Morrison WH, Phan J, Rosenthal DI, Garden AS. Outcomes after salvage for HPV-positive recurrent oropharyngeal cancer treated with primary radiation. Oral Oncol. 2021 02; 113:105125. PMID: 33360375.
      Citations: 2     Fields:    Translation:Humans
    17. Mott FE, Sacks R, Johnson F, Hutcheson KA, Gallagher N, Varghese S, Zaveri J. Subjective functional outcomes in oropharyngeal cancer treated with induction chemotherapy using the MD Anderson Symptom Inventory (MDASI). Laryngoscope Investig Otolaryngol. 2020 Dec; 5(6):1104-1109. PMID: 33364400.
      Citations: 1     
    18. Cardoso RC, Kamal M, Zaveri J, Chambers MS, Gunn GB, Fuller CD, Lai SY, Mott FE, McMillan H, Hutcheson KA. Self-Reported Trismus: prevalence, severity and impact on quality of life in oropharyngeal cancer survivorship: a cross-sectional survey report from a comprehensive cancer center. Support Care Cancer. 2021 Apr; 29(4):1825-1835. PMID: 32779007.
      Citations: 1     Fields:    Translation:Humans
    19. Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, Altan M, Elamin YY, Fossella FV, Kurie JM, Lu C, Mott FE, Tsao AS, Rinsurongkawong W, Lewis J, Gibbons DL, Glisson BS, Blumenschein GR, Roarty EB, Futreal PA, Wistuba II, Roth JA, Swisher SG, Papadimitrakopoulou VA, Heymach JV, Lee JJ, Simon GR, Zhang J. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol. 2020 09; 15(9):1449-1459. PMID: 32389639.
      Citations: 39     Fields:    Translation:Humans
    20. Cascone T, Sepesi B, Lin HY, Kalhor N, Parra ER, Jiang M, Godoy MCB, Zhang J, Fossella FV, Tsao AS, Lam VK, Lu C, Mott FE, Simon GR, Antonoff MB, Mehran RJ, Rice DC, Behrens C, Weissferdt A, Moran C, Vaporciyan AA, Lee JJ, Swisher SG, Gibbons DL, Wistuba II, William WN, Heymach JV. A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 07 15; 26(14):3525-3536. PMID: 32193228.
      Citations: 7     Fields:    Translation:HumansCells
    21. El-Osta HE, Mott FE, Burt BM, Wang DY, Sabichi AL. Predictors of benefits from frontline chemoimmunotherapy in stage IV non-small-cell lung cancer: a meta-analysis. Oncoimmunology. 2019; 8(12):e1665974. PMID: 31741764.
      Citations: 7     Fields:    
    22. Pelster MS, Mott F, Lewin J. Pembrolizumab-induced mucositis in a patient with recurrent hypopharynx squamous cell cancer. Laryngoscope. 2020 04; 130(4):E140-E143. PMID: 31074845.
      Citations: 3     Fields:    Translation:Humans
    23. Mott FE, Adams KC. Advance Care Planning and End-of-Life Issues in Head and Neck Cancer. J Palliat Care. 2019 Jan; 34(1):18-20. PMID: 30016909.
      Citations: 2     Fields:    Translation:Humans
    24. Ng SP, Johnson JM, Gunn GB, Rosenthal DI, Skinner HD, Phan J, Frank SJ, Morrison W, Sturgis EM, Mott FE, Williams MD, Fuller CD, Garden AS. Significance of Negative Posttreatment 18-FDG PET/CT Imaging in Patients With p16/HPV-Positive Oropharyngeal Cancer. Int J Radiat Oncol Biol Phys. 2018 11 15; 102(4):1029-1035. PMID: 29960060.
      Citations: 7     Fields:    Translation:HumansCells
    25. Mott FE, Ferrarotto R, Nguyen T, Phan J. Nasopharyngeal carcinoma outcome with induction chemotherapy followed by concurrent chemoradiotherapy. Oral Oncol. 2018 06; 81:75-80. PMID: 29884417.
      Citations: 4     Fields:    Translation:Humans
    26. Kim CR, Kim B, Ning MS, Reddy JP, Liao Z, Tang C, Welsh JW, Mott FE, Shih YT, Gomez DR. Cost Analysis of PET/CT Versus CT as Surveillance for Stage III Non-Small-Cell Lung Cancer After Definitive Radiation Therapy. Clin Lung Cancer. 2018 07; 19(4):e517-e528. PMID: 29685701.
      Citations: 2     Fields:    Translation:Humans
    27. Mott FE. Patient Reported Outcomes (PROs) as Part of Value-Based Care Can Shape Therapy Guidelines: Impact on Emerging Targeted Agents and Immunotherapy Protocols in Resource-Limited Regions. Oncol Ther. 2017; 5(1):69-74. PMID: 28680956.
      Citations: 3     
    28. Zhao J, Xia Y, Kaminski J, Hao Z, Mott F, Campbell J, Sadek R, Kong FM. Treatment-Related Death during Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Studies. PLoS One. 2016; 11(6):e0157455. PMID: 27300551.
      Citations: 4     Fields:    Translation:Humans
    29. Mott FE, Marcus JD. The final goodbye. Palliat Support Care. 2013 Jun; 11(3):277-9. PMID: 23046864.
      Citations: 1     Fields:    Translation:Humans
    30. Bansal M, Boyle T, Ehsan A, Mott FE. Brain metastases in N2-positive non-small-cell lung cancer: implications for prophylactic cranial irradiation. Clin Lung Cancer. 2008 Jul; 9(4):227-9. PMID: 18650171.
      Citations:    Fields:    Translation:Humans
    31. Mott FE, Cable CT, Sharma N. Phase II study of an alternate carboplatin and gemcitabine dosing schedule in advanced non-small-cell lung cancer. Clin Lung Cancer. 2003 Nov; 5(3):174-6. PMID: 14667273.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    32. Pulmonary embolism following outpatient vasectomy. Current Urology. 9:51-53.
    33. Treatment-related death during concurrent chemoradiotherapy for locally advanced non-small cell lung cancer. PLoS One. 11.
    34. Difficult conversations. Ochsner Journal. 14:712-717.
    35. Pemetrexed and communicating hydrocephalus. Ochsner Journal. 14:292-294.
    MOTT's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (102)
    Explore
    _
    Co-Authors (74)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _